Interview: Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
Allergan India Private Limited, a joint venture between Allergan and Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited), commenced commercial operations in 1996. Allergan India is a specialty pharmaceutical company. It has emerged as the market leader in the fast growing ophthalmic category with the successful launches of a series of high technology medication and devices for diseases such as glaucoma, dry eye, infections and inflammations. Allergan India is today the partner of choice for majority of the Ophthalmologists in the country. Allergan India is poised to grow at a rapid pace. Allergan is the undisputed leader in the Eyecare pharma market with dominance in all major disease segments.
Contact:
Address: No.3, Kasturba Road, Level 2, Prestige Obelisk, Bangalore – 560 001. KARNATAKA, INDIA
Website: https://www.allergan.co.in/hi-in/about/contact-us
Email: IN-Allergan@Allergan.com
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
“India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub.” For Dilip Shah, General…
See our Cookie Privacy Policy Here
